Federal Register / Vol. 86, No. 27 / Thursday, February 11, 2021 / Notices 9077 

development, validation, or appropriate 

use of innovative Lyme disease 

diagnostic tests, and what factors are 

most critical to ensure their success? 

This information will inform the 

development of the HHS Lyme 

Innovation initiative and the LymeX 

public-private partnership to create 

meaningful incentives to develop or 

validate new diagnostic tests for Lyme 

disease. 

Kristen Honey, 

Senior Advisor to the Assistant Secretary for 

Health (ASH), Office of the Assistant 

Secretary for Health, U.S. Department of 

Health and Human Service. 

[FR Doc. 2021–02796 Filed 2–10–21; 8:45 am] 

BILLING CODE 4150–28–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

[Document Identifier OS–0990–xxxx] 

Agency Information Collection 

Request. 60-Day Public Comment 

Request 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: In compliance with the 

requirement of the Paperwork 

Reduction Act of 1995, the Office of the 

Secretary (OS), Department of Health 

and Human Services, is publishing the 

following summary of a proposed 

collection for public comment. 

DATES: Comments on the ICR must be 

received on or before April 12, 2021. 

ADDRESSES: Submit your comments to 

Sherrette.Funn@hhs.gov or by calling 

(202) 795–7714. 

FOR FURTHER INFORMATION CONTACT: 

When submitting comments or 

requesting information, please include 

the document identifier 0990-New-60D, 

and project title for reference, to 

Sherrette Funn, Reports Clearance 

Officer, Sherrette.funn@hhs.gov, 202– 

795–7714. 

SUPPLEMENTARY INFORMATION: Interested 

persons are invited to send comments 

regarding this burden estimate or any 

other aspect of this collection of 

information, including any of the 

following subjects: (1) The necessity and 

utility of the proposed information 

collection for the proper performance of 

the agency’s functions; (2) the accuracy 

of the estimated burden; (3) ways to 

enhance the quality, utility, and clarity 

of the information to be collected; and 

(4) the use of automated collection 

techniques or other forms of information 

technology to minimize the information 

collection burden. 

Title of the Collection: Family 

Planning Annual Report 2.0. 

Type of Collection: New. 

Abstract: The Office of Population 

Affairs (OPA), within the Office of the 

Assistant Secretary for Health, seeks 

approval for a new encounter level data 

collection for the Family Planning 

Annual Report (FPAR). Currently 

collected in aggregate under OMB No. 

0990–0221, this new data collection, 

‘‘FPAR 2.0’’, will collect information at 

the encounter level and build on the 

existing data collection and reporting 

system. This annual reporting 

requirement is for competitively 

awarded grants authorized and funded 

by the Title X Family Planning Program. 

Need and Proposed Use of the 

Information: The Office of Population 

Affairs’ (OPA) Title X Family Planning 

Program is the only federal grant 

program dedicated solely to providing 

comprehensive family planning and 

related preventive health services. 

Annual submission of the FPAR is 

required of all Title X family planning 

services grantees for purposes of 

monitoring and reporting program 

performance (45 CFR part 74 and 45 

CFR part 92). The FPAR is the only 

source of annual, uniform reporting by 

all grantees funded under Section 1001 

of the Title X Public Health Service Act. 

Similar to the previous FPAR, FPAR 2.0 

will provide consistent, national-level 

data on the Title X Family Planning 

program and its users. OPA will be able 

to assemble and analyze comparable 

and relevant program data to answer 

questions about the characteristics of 

the population served, the provision 

and use of services, and the impact of 

the program on certain family planning 

outcomes. FPAR 2.0 will also collect a 

standard set of data elements pertaining 

to users and encounters, such as user 

demographics, service delivery, family 

planning intentions and methods, and 

other indicators, which allow for 

comparisons over time at all levels of 

the program (e.g., national, regional, 

state, and grantee). Encounter level data 

collected through FPAR 2.0 will 

ultimately improve the quality of data 

reported to OPA and reduce reporting 

burden by grantees. Additionally, the 

more granular data collected with FPAR 

2.0 will help contribute to a learning 

healthcare environment by greatly 

expanding the options for data analysis 

and reporting—for example, through 

interactive data dashboards and 

visualizations, customized tabulations 

and reports, and application of analytics 

and statistical analyses on the 

encounter-level data files. 

Information from FPAR 2.0 is 

important to OPA for many reasons, and 

will be used to: 

(1) Monitor compliance with statutory 

requirements, regulations, and 

operational guidance. 

(2) Comply with accountability and 

federal performance requirements for 

Title X family planning funds. 

(3) Guide strategic and financial 

planning, to monitor performance, to 

respond to inquiries from policymakers 

and Congress about the program, and to 

estimate program impact. 

Type of respondent: Annual reporting; 

respondents are all grantees that receive 

Title X funding from OPA. 

ANNUALIZED BURDEN HOUR TABLE

Forms 

(if necessary) 

Respondents 

(if necessary) 

Number of 

respondents 

Number of 

responses per 

respondents 

Average 

burden per 

response 

Total burden 

hours 

FPAR 2.0 .......................................... Grantees ........................................... 74 1 36 2,664 

Total ........................................... ........................................................... ........................ 1 ........................ 2,664 


khammond on DSKJM1Z7X2PROD with NOTICES
9078 Federal Register / Vol. 86, No. 27 / Thursday, February 11, 2021 / Notices 

Sherrette A. Funn, 

Office of the Secretary, Paperwork Reduction 

Act Reports Clearance Officer. 

[FR Doc. 2021–02825 Filed 2–10–21; 8:45 am] 

BILLING CODE 4150–34–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Board of Scientific 

Counselors, National Cancer Institute. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Cancer Institute, including 

consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, National Cancer Institute. 

Date: March 9, 2021. 

Time: 11:00 a.m. to 5:40 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: National Cancer Institute, Shady 

Grove, 9609 Medical Center Drive, Rockville, 

MD 20850, (Virtual Meeting). 

Contact Person: Brian E. Wojcik, Ph.D., 

Executive Secretary, Institute Review Office, 

Office of the Director, National Cancer 

Institute, National Institutes of Health, 9609 

Medical Center Drive, Room 3W414, 

Rockville, MD 20850, 240–276– 

5660,wojcikb@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: February 5, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–02791 Filed 2–10–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Human 

Genome Research Institute Initial Review 

Group; Genome Research Review Committee 

GNOM. 

Date: March 11, 2021. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Human Genome Research 

Institute, National Institutes of Health, 6700B 

Rockledge Drive, Greider Conference Room 

3189, Bethesda, MD 20892, Telephone: 301– 

594–4280, Fax: 301–435–1580, (Virtual 

Meeting). 

Contact Person: Keith McKenney, Ph.D. 

Scientific Review Officer, National Human 

Genome Research Institute, National 

Institutes of Health, 6700B Rockledge Drive, 

Bethesda, MD 20817, 301–594–4280 

mckenneyk@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: February 5, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–02784 Filed 2–10–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel; Single Cell Mapping Centers and Data 

Coordinating Center. 

Date: March 18, 2021. 

Time: 10:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Human Genome Research 

Institute, National Institutes of Health, 6700B 

Rockledge Drive, Greider Conference Room 

3189, Bethesda, MD 20892, Telephone: 301– 

594–4280, Fax: 301–435–1580 (Virtual 

Meeting). 

Contact Person: Keith McKenney, Ph.D., 

Scientific Review Officer, National Human 

Genome Research Institute, National 

Institutes of Health, 6700B Rockledge Drive, 

Bethesda, MD 20817 301–594–4280, 

mckenneyk@mail.nih.gov. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel; Predictive Modeling—SEP. 

Date: March 23, 2021. 

Time: 10:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Human Genome Research 

Institute, National Institutes of Health, 6700B 

Rockledge Drive, Greider Conference Room 

3189, Bethesda, MD 20892, Telephone: 301– 

594–4280, Fax: 301–435–1580 (Virtual 

Meeting). 

Contact Person: Keith McKenney, Ph.D., 

Scientific Review Officer, National Human 

Genome Research Institute, National 

Institutes of Health, 6700B Rockledge Drive, 

Bethesda, MD 20817 301–594–4280 

mckenneyk@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: February 5, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–02787 Filed 2–10–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 


khammond on DSKJM1Z7X2PROD with NOTICES